Literature DB >> 27293807

Registry to evaluate early and long-term disease management in PAH (REVEAL).

Balaji Pakshirajan1, Ajit S Mullasari1.   

Abstract

Year:  2016        PMID： 27293807      PMCID： PMC4886003          DOI： 10.21037/jtd.2016.04.07

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

Review 1.  Thrombotic arteriopathy and anticoagulation in pulmonary hypertension.

Authors:  Sindhu R Johnson; John T Granton; Sanjay Mehta
Journal:  Chest       Date:  2006-08       Impact factor: 9.410

Review 2.  Immune dysregulation and endothelial dysfunction in pulmonary arterial hypertension: a complex interplay.

Authors:  Alice Huertas; Frédéric Perros; Ly Tu; Sylvia Cohen-Kaminsky; David Montani; Peter Dorfmüller; Christophe Guignabert; Marc Humbert
Journal:  Circulation       Date:  2014-03-25       Impact factor: 29.690

3.  Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension.

Authors:  A Campo; S C Mathai; J Le Pavec; A L Zaiman; L K Hummers; D Boyce; T Housten; N Lechtzin; H Chami; R E Girgis; P M Hassoun
Journal:  Eur Respir J       Date:  2011-02-10       Impact factor: 16.671

4.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

5.  Primary pulmonary hypertension: natural history and the importance of thrombosis.

Authors:  V Fuster; P M Steele; W D Edwards; B J Gersh; M D McGoon; R L Frye
Journal:  Circulation       Date:  1984-10       Impact factor: 29.690

6.  Do patients with primary pulmonary hypertension develop extensive central thrombi?

Authors:  K M Moser; P F Fedullo; W E Finkbeiner; J Golden
Journal:  Circulation       Date:  1995-02-01       Impact factor: 29.690

7.  Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors:  Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

8.  Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

Authors:  Yi Ling; Martin K Johnson; David G Kiely; Robin Condliffe; Charlie A Elliot; J Simon R Gibbs; Luke S Howard; Joanna Pepke-Zaba; Karen K K Sheares; Paul A Corris; Andrew J Fisher; James L Lordan; Sean Gaine; J Gerry Coghlan; S John Wort; Michael A Gatzoulis; Andrew J Peacock
Journal:  Am J Respir Crit Care Med       Date:  2012-07-12       Impact factor: 21.405

9.  Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

Authors:  Ioana R Preston; Kari E Roberts; Dave P Miller; Ginny P Sen; Mona Selej; Wade W Benton; Nicholas S Hill; Harrison W Farber
Journal:  Circulation       Date:  2015-10-28       Impact factor: 29.690

10.  Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Authors:  Marius M Hoeper; Robyn J Barst; Robert C Bourge; Jeremy Feldman; Adaani E Frost; Nazzareno Galié; Miguel Angel Gómez-Sánchez; Friedrich Grimminger; Ekkehard Grünig; Paul M Hassoun; Nicholas W Morrell; Andrew J Peacock; Toru Satoh; Gérald Simonneau; Victor F Tapson; Fernando Torres; David Lawrence; Deborah A Quinn; Hossein-Ardeschir Ghofrani
Journal:  Circulation       Date:  2013-02-12       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.